PAB Patrys Limited
Unknown sector · Pharmaceuticals, Biotechnology & Life Sciences
· website
$0.03
52wk 0.03 – 0.05
Overall
35.6
Value
45.5
Growth
0.0
Health
100.0
Quality
0.0
Momentum
19.4
Dividend
—
Price
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | -17.5% |
| 1 month | -15.4% |
| 3 months | 6.5% |
| 6 months | 0.0% |
| 1 year | — |
| 3 years | — |
Risk
| Volatility (1y ann.) | 91.7% |
| Beta vs ASX 200 | 1.38 |
| Sharpe (1y) | 0.31 |
| VaR 95% (1-day) | -7.9% |
| Max drawdown (1y) | -44.4% |
| Off 1-year high | -32.7% |
Technicals
| RSI(14) | 35 |
| vs 50DMA | -17.9% |
| vs 200DMA | — |
| Trend | — |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(4 Aug 2026)
Value
45.5
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
19.4
6-month return vs ASX 200
11
Price vs 200-day average
36
Price vs 50-day average
0
Position in 52-week range
30
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$11.57M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
—
Beta
1.26
EV / EBITDA
-2.24
Price / Book
8.25
ROE
-260.6%
Operating margin
-131,356.6%
Net margin
0.0%
Total cash
$1.90M
Total debt
$0
Current ratio
3.80
Debt / Equity
—
Free cash flow
$-974,707
Avg volume
919,942
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$3.54M
- Net income-$3.01M
- Diluted EPS—
- Free cash flow-$1.77M
- Net debt-$742.44K